S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
Log in
NASDAQ:STTK

Shattuck Labs Stock Forecast, Price & News

$24.79
-0.40 (-1.59 %)
(As of 10/29/2020 03:03 PM ET)
Add
Compare
Today's Range
$24.40
Now: $24.79
$25.30
50-Day Range N/A
52-Week Range
$17.51
Now: $24.79
$25.72
Volume6,750 shs
Average Volume188,066 shs
Market Capitalization$990.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STTK
CUSIPN/A
CIKN/A
Phone919 864 2700
Employees45

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$990.66 million
Next Earnings DateN/A
OptionableNot Optionable
$24.79
-0.40 (-1.59 %)
(As of 10/29/2020 03:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STTK News and Ratings via Email

Sign-up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Shattuck Labs (NASDAQ:STTK) Frequently Asked Questions

Who are some of Shattuck Labs' key competitors?

Who are Shattuck Labs' key executives?

Shattuck Labs' management team includes the following people:
  • Mr. Josiah C. Hornblower, Co-Founder & Exec. Chairman (Age 44)
  • Dr. Taylor H. Schreiber, Co-Founder, CEO & Director (Age 40)
  • Mr. Andrew R. Neill M.B.A., VP of Fin. & Corp. Strategy (Age 34)
  • Ms. Erin Ator Thomson J.D., Gen. Counsel (Age 40)
  • Dr. Arundathy Nirmalini Pandite, Chief Medical Officer (Age 61)

When did Shattuck Labs IPO?

(STTK) raised $150 million in an initial public offering on Friday, October 9th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI served as the underwriters for the IPO and Needham & Co. was co-manager.

What is Shattuck Labs' stock symbol?

Shattuck Labs trades on the NASDAQ under the ticker symbol "STTK."

When does Shattuck Labs' quiet period expire?

Shattuck Labs' quiet period expires on Wednesday, November 18th. Shattuck Labs had issued 11,882,352 shares in its IPO on October 9th. The total size of the offering was $201,999,984 based on an initial share price of $17.00. During Shattuck Labs' quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Shattuck Labs?

Shares of STTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Shattuck Labs' stock price today?

One share of STTK stock can currently be purchased for approximately $25.00.

How big of a company is Shattuck Labs?

Shattuck Labs has a market capitalization of $999.05 million. Shattuck Labs employs 45 workers across the globe.

What is Shattuck Labs' official website?

The official website for Shattuck Labs is www.shattucklabs.com.

How can I contact Shattuck Labs?

The company can be reached via phone at 919 864 2700.

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.